Correcting this MUFA imbalance with SCD inhibitor treatment reversed PD-relevant phenotypes in vitro and in vivo, and an SCD inhibitor subsequently entered PD clinical trials (22, 44–46, 55, 57, 58). This evidence concerns the gene SCD and Parkinson disease.